Prevalence of key resistance mutations K65R, K103N, and M184V as minority HIV-1 variants in chronically HIV-1 infected, treatment-naïve patients

Journal of Clinical Virology

Volumn 50, Issue 2, 2011, Pages 156-161

  Metzner, Karin J ^a,b   Rauch, Pia ^a   Braun, Patrick ^c   Knechten, Heribert ^c   Ehret, Robert ^c   Korn, Klaus ^a   Kaiser, Rolf ^d   Sichtig, Nadine ^d   Ranneberg, Britta ^e   van Lunzen, Jan ^f   Walter, Hauke ^a  

^a UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

^b UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^c Praxis Zentrum Blondelstrasse   (Germany)

^d UNIVERSITY OF COLOGNE   (Germany)

^e Gilead Sciences GmbH   (Germany)

^f UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

Author keywords

Allele specific real time PCR; ART; Drug resistance; HIV 1; Minority drug resistant HIV 1 variants; Treatment failure

Indexed keywords

EMTRICITABINE; RITONAVIR; TENOFOVIR DISOPROXIL;

ARTICLE; CHRONIC DISEASE; FEMALE; GENE FREQUENCY; GENE MUTATION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PREVALENCE; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION; TREATMENT FAILURE; TREATMENT OUTCOME;

ALLELES; ANTI-HIV AGENTS; DRUG RESISTANCE, VIRAL; FEMALE; GENETIC VARIATION; GENOTYPE; GERMANY; HIV INFECTIONS; HIV-1; HUMANS; MALE; MUTATION; POLYMERASE CHAIN REACTION; TREATMENT OUTCOME;

EID: 78951491603     PISSN: 13866532     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jcv.2010.10.001     Document Type: Article

References (34)

1. Egger M., Hirschel B., Francioli P., Sudre P., Wirz M., Flepp M., et al. Impact of new antiretroviral combination therapies in HIV infected patients in Switzerland: prospective multicentre study. Swiss HIV Cohort Study. BMJ 1997, 315:1194-1199.
2. Flexner C. HIV drug development: the next 25 years. Nat Rev Drug Discov 2007, 6:959-966.
3. Daar E.S., Richman D.D. Confronting the emergence of drug-resistant HIV Type 1: impact of antiretroviral therapy on individual and population resistance. AIDS Res Hum Retroviruses 2005, 21:343-357.
4. Metzner K.J. Persistence of drug-resistant HIV-1 and possible implications for antiretroviral therapy. Future Virol 2006, 1:377-391.
5. Little S.J., Holte S., Routy J.P., Daar E.S., Markowitz M., Collier A.C., et al. Antiretroviral-drug resistance among patients recently infected with HIV. N Engl J Med 2002, 347:385-394.
6. Yerly S., Kaiser L., Race E., Bru J.P., Clavel F., Perrin L. Transmission of antiretroviral-drug-resistant HIV-1 variants. Lancet 1999, 354:729-733.
7. Yerly S., von Wyl V., Ledergerber B., Boni J., Schupbach J., Burgisser P., et al. Transmission of HIV-1 drug resistance in Switzerland: a 10-year molecular epidemiology survey. AIDS 2007, 21:2223-2229.
8. Hirsch M.S., Gunthard H.F., Schapiro J.M., Brun-Vezinet F., Clotet B., Hammer S.M., et al. Antiretroviral drug resistance testing in adult HIV-1 infection: 2008 recommendations of an International AIDS Society-USA panel. Clin Infect Dis 2008, 47:266-285.
9. Kaufmann G.R., Khanna N., Weber R., Perrin L., Furrer H., Cavassini M., et al. Long-term virological response to multiple sequential regimens of highly active antiretroviral therapy for HIV infection. Antivir Ther 2004, 9:263-274.
10. Nicastri E., Chiesi A., Angeletti C., Sarmati L., Palmisano L., Geraci A., et al. Clinical outcome after 4 years follow-up of HIV-seropositive subjects with incomplete virologic or immunologic response to HAART. J Med Virol 2005, 76:153-160.
11. Gunthard H.F., Wong J.K., Ignacio C.C., Havlir D.V., Richman D.D. Comparative performance of high-density oligonucleotide sequencing and dideoxynucleotide sequencing of HIV type 1 pol from clinical samples. AIDS Res Hum Retroviruses 1998, 14:869-876.
12. Schuurman R., Demeter L., Reichelderfer P., Tijnagel J., de Groot T., Boucher C. Worldwide evaluation of DNA sequencing approaches for identification of drug resistance mutations in the human immunodeficiency virus type 1 reverse transcriptase. J Clin Microbiol 1999, 37:2291-2296.
13. Metzner K.J. Detection and significance of minority quasispecies of drug-resistant HIV-1. J HIV Ther 2006, 11:74-81.
14. Johnson J.A., Li J.F., Wei X., Lipscomb J., Irlbeck D., Craig C., et al. Minority HIV-1 drug resistance mutations are present in antiretroviral treatment-naive populations and associate with reduced treatment efficacy. PLoS Med 2008, 5:e158.
15. Peuchant O., Thiebaut R., Capdepont S., Lavignolle-Aurillac V., Neau D., Morlat P., et al. Transmission of HIV-1 minority-resistant variants and response to first-line antiretroviral therapy. AIDS 2008, 22:1417-1423.
16. Metzner K.J., Giulieri S.G., Knoepfel S.A., Rauch P., Burgisser P., Yerly S., et al. Minority quasispecies of drug-resistant HIV-1 that lead to early therapy failure in treatment-naive and -adherent patients. Clin Infect Dis 2009, 48:239-247.
17. Simen B.B., Simons J.F., Hullsiek K.H., Novak R.M., Macarthur R.D., Baxter J.D., et al. Low-abundance drug-resistant viral variants in chronically HIV-infected, antiretroviral treatment-naive patients significantly impact treatment outcomes. J Infect Dis 2009, 199:693-701.
18. Balduin M., Oette M., Daumer M.P., Hoffmann D., Pfister H.J., Kaiser R. Prevalence of minor variants of HIV strains at reverse transcriptase position 103 in therapy-naive patients and their impact on the virological failure. J Clin Virol 2009, 45:34-38.
19. Carr J.M., Green T., Shaw D., Daly L., Hart W., Ratcliff R., et al. Application of an allele-specific PCR to clinical HIV genotyping samples detects additional K103N mutations in both therapy naive and experienced patients. J Med Virol 2009, 81:1983-1990.
20. Metzner K.J., Rauch P., von Wyl V., Leemann C., Grube C., Kuster H., et al. Efficient suppression of minority drug-resistant HIV Type 1 (HIV-1) variants present at primary HIV-1 infection by ritonavir-boosted protease inhibitor-containing antiretroviral therapy. J Infect Dis 2010, 201:1063-1071.
21. Luber A.D. Genetic barriers to resistance and impact on clinical response. Med Gen Med 2005, 7:69.
22. Van Lunzen J., Fatkenheuer G., Lutz T., Klauke S., Mauss S., Knechten H., et al. Efficacy and tolerability of TDF/FTC-containing first line HAART in clinical practice: 2 year data from the German outpatient cohort. 9th International Congress on Drug Therapy in HIV Infection 2008.
23. Johnson V.A., Brun-Vezinet F., Clotet B., Gunthard H.F., Kuritzkes D.R., Pillay D., et al. Update of the drug resistance mutations in HIV-1. Top HIV Med 2008, 16:138-145.
24. Metzner K.J., Bonhoeffer S., Fischer M., Karanicolas R., Allers K., Joos B., et al. Emergence of minor populations of human immunodeficiency virus type 1 carrying the M184V and L90M mutations in subjects undergoing structured treatment interruptions. J Infect Dis 2003, 188:1433-1443.
25. Metzner K.J., Rauch P., Walter H., Boesecke C., Zollner B., Jessen H., et al. Detection of minor populations of drug-resistant HIV-1 in acute seroconverters. AIDS 2005, 19:1819-1825.
26. Cheung P.K., Wynhoven B., Harrigan PR which HIV-1 drug resistance mutations are common in clinical practice?. AIDS Rev 2004, 6:107-116.
27. Oette M., Kaiser R., Daumer M., Petch R., Fatkenheuer G., Carls H., et al. Primary HIV drug resistance and efficacy of first-line antiretroviral therapy guided by resistance testing. J Acquir Immune Defic Syndr 2006, 41:573-581.
28. Nicastri E., Sarmati L., d'Ettorre G., Palmisano L., Parisi S.G., Uccella I., et al. Replication capacity, biological phenotype, and drug resistance of HIV strains isolated from patients failing antiretroviral therapy. J Med Virol 2003, 69:1-6.
29. Deval J., White K.L., Miller M.D., Parkin N.T., Courcambeck J., Halfon P., et al. Mechanistic basis for reduced viral and enzymatic fitness of HIV-1 reverse transcriptase containing both K65R and M184V mutations. J Biol Chem 2004, 279:509-516.
30. Toni T.A., Asahchop E.L., Moisi D., Ntemgwa M., Oliveira M., Masquelier B., et al. Detection of human immunodeficiency virus (HIV) type 1 M184V and K103N minority variants in patients with primary HIV infection. Antimicrob Agents Chemother 2009, 53:1670-1672.
31. Goodman D.D., Margot N.A., McColl D.J., Miller M.D., Borroto-Esoda K., Svarovskaia E.S. Pre-existing low-levels of the K103N HIV-1 RT mutation above a threshold is associated with virological failure in treatment-naive patients undergoing EFV-containing antiretroviral treatment. Antivir Ther 2009, 14:A43. (abstract 41, XVIII International HIV Drug Resistance Workshop 2009).
32. Geretti A.M., Fox Z.V., Booth C.L., Smith C.J., Phillips A.N., Johnson M., et al. Low-frequency K103N strengthens the impact of transmitted drug resistance on virologic responses to first-line efavirenz or nevirapine-based highly active antiretroviral therapy. J Acquir Immune Defic Syndr 2009, 52:569-573.
33. Paredes R., Lalama C.M., Ribaudo H.J., Schackman B.R., Shikuma C., Giguel F., et al. Pre-existing minority drug-resistant HIV-1 variants, adherence, and risk of antiretroviral treatment failure. J Infect Dis 2010, 201:662-671.
34. Bushman F.D., Hoffmann C., Ronen K., Malani N., Minkah N., Rose H.M., et al. Massively parallel pyrosequencing in HIV research. AIDS 2008, 22:1411-1415.